BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23478586)

  • 1. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
    Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
    Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.
    Bagni O; Filippi L; Pelle G; Cianni R; Schillaci O
    Cancer Biother Radiopharm; 2015 Dec; 30(10):421-6. PubMed ID: 26594900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
    Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
    Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
    Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
    Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.
    Kucuk ON; Soydal C; Araz M; Bilgic S; Ibis E
    Clin Nucl Med; 2013 Jul; 38(7):e283-9. PubMed ID: 23531737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
    Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
    HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases.
    Muralidharan V; Kwok M; Lee ST; Lau L; Scott AM; Christophi C
    J Nucl Med; 2012 Sep; 53(9):1345-51. PubMed ID: 22797376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
    Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
    World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
    Tochetto SM; Töre HG; Chalian H; Yaghmai V
    AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
    Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D
    Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
    Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
    Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.